Pharma BD Deal Intelligence

Sandoz AG / Samsung Bioepis Co., Ltd.

2026 · Licensing/Option · Complete

Sandoz and Samsung Bioepis entered a licence, development and commercialization agreement covering up to five next-generation biosimilar candidates. Sandoz receives exclusive rights to commercialize the biosimilars globally excluding China, Hong Kong, Taiwan, Macau and the Republic of Korea, while Samsung Bioepis is responsible for development, manufacturing and regulatory submissions in key markets. The first candidate licensed under the agreement is SB36, a pre-clinical biosimilar candidate referencing Takeda's Entyvio (vedolizumab). Financial terms were not disclosed. The two companies previously partnered in September 2023 on Pyzchiva/SB17, a biosimilar to Johnson & Johnson's Stelara (ustekinumab).

Key facts

• Announced Mar 18, 2026
• Deal type Licensing/Option
• Therapeutic area Immunology
• Indications Inflammatory bowel disease (reference product Entyvio / vedolizumab)
• Key assets Up to five next-generation biosimilar candidates; first is SB36, a biosimilar candidate referencing Takeda's Entyvio (vedolizumab)
• Mechanism Anti-alpha4beta7 integrin monoclonal antibody (vedolizumab biosimilar)

Related deals

• Amgen Inc. / Immunex Corporation (2002)
• PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG (2017)
• Vertex Pharmaceuticals Inc. / Alpine Immune Sciences (2024)
• Roche Holding AG / Genentech, Inc. (2009)
• Travere Therapeutics, Inc. / Everest Medicines Limited (2026)
• Amgen Inc. / Horizon Therapeutics plc (2022)

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Immunology deals